GlassScriptPhysician profile
Jared R Heaton
NPI 1457666562
$3,082.18
in general payments reported to CMS, 2019-2025
26 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $520 · 2021: $472 · 2022: $217 · 2023: $114 · 2024: $442 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $376.28 | 2019-2023 | |
| Allergan, INC. | $347.90 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $240.04 | 2019-2022 | |
| Pfizer INC. | $207.53 | 2019-2021 | |
| Lilly USA, LLC | $182.48 | 2019-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $155.61 | 2019-2024 | Tremfya |
| Incyte Corporation | $135.24 | 2024 | Opzelura |
| Prugen, INC. Pharmaceuticals | $129.41 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $126.71 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $118.10 | 2021-2022 | |
| Ucb, INC. | $103.90 | 2019-2025 | Bimzelx |
| Biofrontera INC. | $82.56 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $73.22 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $69.31 | 2020-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $53.08 | 2021-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $33.13 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $30.58 | 2024 | Vtama |
| Genentech USA, INC. | $27.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.42 | 2024 | Spevigo |
| Amgen INC. | $19.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.96 | 2021 | |
| Organon LLC | $17.69 | 2025 | Vtama |
| Smith+Nephew, INC. | $15.62 | 2021 | |
| Vyne Pharmaceuticals INC. | $11.45 | 2021 | |
| Organogenesis INC. | $9.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.